New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 300000 tcid50; polio virus type 2 100000 tcid50; polio virus type 3 300000 tcid50 - oral suspension - 0.5 ml - active: polio virus type 1 300000 tcid50 polio virus type 2 100000 tcid50 polio virus type 3 300000 tcid50 excipient: albumin magnesium chloride hexahydrate phenolsulfonphthalein

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - poliomyelitis virus (sabin strain) type min 1000000 tcid50/0.5 ml - suspension - min 1000000 tcid50/0.5 ml

Canada - English - Health Canada

sanofi pasteur limited - inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney - solution - 8unit; 32unit; 40unit - inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit - vaccines

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - virus polio type 1, strain lsc, 2ab; virus polio type 3, strain leon 12a, 1b - suspension - virus polio type 1, strain lsc, 2ab ≥10⁶·˚ccid₅₀; virus polio type 3, strain leon 12a, 1b ≥10⁵·⁸ccid₅₀

New Zealand - English - Medsafe (Medicines Safety Authority)

specialised therapeutics limited - aminolevulinic acid hydrochloride 1.5 g - powder for oral solution - 1.5 g - active: aminolevulinic acid hydrochloride 1.5 g - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (gbm) on preoperative imaging , and who are intended for resection of the tumour.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - 5-aminolevulinic acid hydrochloride - powder for solution - 5-aminolevulinic acid hydrochloride 1.5 g - aminolevulinic acid - gliolan® is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (who grade iii and iv).

New Zealand - English - Medsafe (Medicines Safety Authority)

biocelect new zealand ltd - salmonella typhi strain ty21a berna 2000 million organisms (minimum); salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum); salmonella typhi strain ty21a berna 2000 million organisms - modified release capsule - 2000 million organisms - active: salmonella typhi strain ty21a berna 2000 million organisms (minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate lactose fast flo iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sucrose titanium dioxide active: salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate sucrose titanium dioxide active: salmonella typhi strain ty21a berna 2000 million organisms excipient: ascorbic acid diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate methanol methylene chloride protein hydrolysate sucrose titanium dioxide - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - powder and suspension for suspension for injection - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - pertussis toxoid; filamentous haemagglutinin; pertactin; diphtheria toxoid; tetanus toxoid; polio virus type 1 inactivated; polio virus type 2 inactivated; polio virus type 3 inactivated - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - diphtheria-pertussis-poliomyelitis-tetanus

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - inactivated poliomyelitis virus type 1 (mahoney); inactivated poliomyelitis virus type 2 (mef-1); inactivated poliomyelitis virus type 3 (saukett) - injection - 8 d.u. - inactivated poliomyelitis virus type 1 (mahoney) 40 d.u./0.5 ml; inactivated poliomyelitis virus type 2 (mef-1) 8 d.u./0.5 ml; inactivated poliomyelitis virus type 3 (saukett) 32 d.u./0.5 ml